Beta Bionics (BBNX) Current Deferred Revenue (2023 - 2026)

Beta Bionics' Current Deferred Revenue history runs 4 years deep, the most recent figure standing at $1.7 million for Q1 2026.

• In Q1 2026, Current Deferred Revenue rose 79.66% year-over-year to $1.7 million; the TTM figure through Mar 2026 stood at $1.7 million (up 79.66% YoY), while the FY2025 annual figure was $1.6 million, up 65.81% from the prior year.
• Current Deferred Revenue came in at $1.7 million for Q1 2026 at Beta Bionics, up from $1.6 million in the prior quarter.
• In the past five years, Current Deferred Revenue ranged from a high of $1.7 million in Q1 2026 to a low of $87000.0 in Q4 2023.
• A 4-year average of $1.1 million and a median of $1.1 million in 2025 frame the typical range for Current Deferred Revenue.
• Across the five-year window, Current Deferred Revenue soared 979.31% in 2024 and jumped 65.81% in 2025, its largest moves.
• Beta Bionics' Current Deferred Revenue stood at $87000.0 in 2023, then jumped by 979.31% to $939000.0 in 2024, then surged by 65.81% to $1.6 million in 2025, then gained by 9.51% to $1.7 million in 2026.
• According to Business Quant data, Current Deferred Revenue over the past three periods registered $1.7 million, $1.6 million, and $1.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison